Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Extension of Ataluren in Nonsense Mutation DMD/BMD
NCT00847379Phase 2Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jan 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of ataluren in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), sponsored by PTC Therapeutics, Inc.. Started Jan 2009; status: terminated.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT00847379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00847379.